تداخلات تامسولوسين

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Avoid coadministration of FANAPT with alpha-adrenergic blocking agents and adjust medications that affect blood pressure as needed [see Warnings and Precautions (5.7) ] . (نشرة إيلوبيريدون، التداخلات الدوائية)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

CIALIS is not recommended in combination with alpha-blockers for the treatment of BPH because efficacy of the combination has not been adequately studied and because of the risk of blood pressure lowering. (نشرة تادالافيل، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions ( 7.2 )… (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Should not be used in combination with strong inhibitors of CYP3A4. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha Blockers: Co-administration of beta-blockers with alpha-blocker (e.g., prazosin) has been associated with prolongation of first dose hypotension and syncope. (نشرة بروبرانولول، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C max and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Exercise caution with concomitant administration of warfarin ( 5.2 , 7.4 , 12.3 ) (نشرة تامسولوسين، التحذيرات والاحتياطات)

• Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (نشرة أدرينالين، التداخلات الدوائية)

Use in Patients with Pheochromocytoma If BREVIBLOC injection is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. (نشرة إسمولول، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy. (نشرة دوتاستيريد، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Pheochromocytoma: Initiate therapy with an alpha blocker. (نشرة ميتوبرولول، التحذيرات والاحتياطات)

Pheochromocytoma: First initiate therapy with an alpha blocker. (نشرة ميتوبرولول وهيدروكلوروثيازيد، التحذيرات والاحتياطات)

Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of midodrine hydrochloride. (نشرة ميدودرين، التداخلات الدوائية)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)